scholarly journals Hospital anxiety and depression scale exhibits good consistency but shorter assessment time than Zung self-rating anxiety/depression scale for evaluating anxiety/depression in non-small cell lung cancer

Medicine ◽  
2021 ◽  
Vol 100 (8) ◽  
pp. e24428
Author(s):  
Congying Guo ◽  
Xuan Huang
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Depression Scale ◽  
Small Cell ◽  
Anxiety And Depression ◽  
Hospital Anxiety ◽  
Small Cell Lung ◽  
Good Consistency ◽  
Assessment Time ◽  
Anxiety Depression

Tumor mutation burden and depression in lung cancer: Association with inflammation.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e23159-e23159
Author(s):  
Daniel Curtis McFarland ◽  
Devika R Jutagir ◽  
Barry Rosenfeld ◽  
Andrew H. Miller ◽  
Christian J. Nelson ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Depression Scale ◽  
Small Cell ◽  
Depression Severity ◽  
Small Cell Lung ◽  
Tumor Mutation Burden ◽  
Lung Cancer Patients ◽  
Mutation Burden

e23159 Background: Depression and inflammation are both associated with lung cancer. Tumor Mutation Burden (TMB) can be used to predict immunotherapy response which relies on tumor immunogenicity, a form of inflammation. This study evaluated whether higher TMB was associated with increased depression and various forms of inflammation. Methods: Patients with metastatic Non-small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) receiving anticancer treatments were evaluated for depression severity using the Hospital Anxiety and Depression Scale (HADS). TMB was measured using Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT). Inflammation was evaluated using C - reactive protein (CRP) and the Neutrophil to Lymphocyte Ratio (NLR). Results: Ninety-six out of 140 participants with adequate TMB testing were evaluated (68.6%). The average number of mutations was 10.8 (SD 10.8). Twenty-four percent met screening criteria for depression. TMB correlated with depression severity (r = .34, p = .001) and NLR (r = .37, p = .002) and absolute neutrophil count (r = .3, p = .006) but not CRP (r = .193, p = .06). TMB was higher in patients receiving chemotherapy (12.0) and immunotherapy (14.4) over targeted therapy (4.8). A multivariate model found that TMB (β = .25, p = .032) and CRP (β = .36, p = .003) predicted for depression severity. Conclusions: TMB is an independent predictor of depression. Inflammatory indices suggest a possible relationship but the exact mechanism should be further evaluated and the results warrant replication. Ultimately, these findings may help identify lung cancer patients at risk for depression. [Table: see text]

scholarly journals Target-Adverse Events and Fear of Cancer Progression, Anxiety, and Depression in Patients with Advanced Non-Small Cell Lung Cancer

2021 ◽  
Author(s):  
Chu Chun Yu ◽  
Chia Yu Chu ◽  
Yeur Hur Lai ◽  
Jui Chun Chan ◽  
Yen Ju Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adverse Events ◽  
Small Cell Lung Cancer ◽  
Cancer Progression ◽  
Small Cell ◽  
Anxiety And Depression ◽  
Small Cell Lung ◽  
Fear Of Cancer ◽  
Nsclc Patients ◽  
Egfr Tkis

Abstract Objective: To examine the difference in levels of fear of cancer progression (FoP), anxiety, depression between presence/absence of the target-adverse events (AEs); and to examine the differences in incidence rate of AEs and FoP, anxiety, and depression among three generations of EGFR-TKIs therapy (first, gefitinib and erlotinib [G1]; second, afatinib [G2]; third, osimertinib [G3]) in non-small-cell lung cancer (NSCLC) patients.Methods: A cross-sectional study design. NSCLC patients (n=128) were recruited from a medical center in Taiwan. A set of structured questionnaires assessing AEs, FoP, anxiety and depression. Results: Parts of AEs, such as photosensitivity, paronychia, and alopecia, exhibited significantly higher levels of FoP, anxiety, and depression. Less patients experienced AEs in the G3 group than those in the G1 or G2 group but still reported experiencing itching, dry skin with grade 3 severity. The incidence rates of mouth/throat sores, and cheilosis/cheilitis in the G2 group was significantly higher than those in the G1 or G3 group. The incidence rate of FoP, anxiety and depression were 13.8-26.3%, 23.8-40.4% and 16.7-42.1%, respectively.Conclusions: The priorities of care among three generations of EGFR-TKIs in patients with NSCLC were established. FoP, anxiety and depression were present among different targeted therapies and require further attention.

Depression in Patients With Lung Cancer: Prevalence and Risk Factors Derived From Quality-of-Life Data

2000 ◽  
Vol 18 (4) ◽  
pp. 893-893 ◽  
Author(s):  
Penelope Hopwood ◽  
Richard J. Stephens ◽  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Performance Status ◽  
Depression Scale ◽  
Working Party ◽  
Small Cell ◽  
Small Cell Lung

PURPOSE: To evaluate self-reported depression rates in patients with inoperable lung cancer and to explore demographic, clinical, and quality-of-life (QOL) factors associated with depression and thus identify patients at risk. PATIENTS AND METHODS: Nine hundred eighty-seven patients from three palliative treatment trials conducted by the Medical Research Council Lung Cancer Working Party formed the study sample. 526 patients (53%) had poor prognosis small-cell lung cancer (SCLC) and 461 patients (47%) had good prognosis non–small-cell lung cancer (NSCLC). Hospital Anxiety and Depression Scale data and QOL items from the Rotterdam Symptom Checklist were analyzed, together with relevant demographic and clinical factors. RESULTS: Depression was self-rated in 322 patients (33%) before treatment and persisted in more than 50% of patients. SCLC patients had a three-fold greater prevalence of case depression than those with NSCLC (25% v 9%; P < .0001). An increased rate for women was found for good performance status (PS) patients (PS of 0 or 1) but the sex difference reduced for poor PS patients (PS of 3 or 4) because of increased depression rates for men (χ2 for trend, P < .0001). Multivariate analysis showed that functional impairment was the most important risk factor; depression increased by 41% for each increment on the impairment scale. Pretreatment physical symptom burden, fatigue, and clinician-rated PS were also independent predictors, but cell type was not. CONCLUSION: Depression is common and persistent in lung cancer patients, especially those with more severe symptoms or functional limitations. Psychologic screening and appropriate intervention is an essential part of palliative care.

Patient-reported short-term and long-term physical and psychologic symptoms: results of the continuous hyperfractionated accelerated [correction of acclerated] radiotherapy (CHART) randomized trial in non-small-cell lung cancer. CHART Steering Committee.

1998 ◽  
Vol 16 (9) ◽  
pp. 3082-3093 ◽  
Author(s):  
A J Bailey ◽  
M K Parmar ◽  
R J Stephens
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Depression Scale ◽  
Small Cell ◽  
Small Cell Lung ◽  
Short Term ◽  
Data Set ◽  
Patient Reported

PURPOSE The randomized multicenter trial of continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy for patients with non-small-cell lung cancer (NSCLC) showed a significant survival benefit to CHART (29% v 20% at 2 years, P=.004). However, an assessment of the effect on physical and psychologic symptoms is vital to balance the costs and benefits of the two treatments. METHODS A total of 356 patients in the United Kingdom completed the Rotterdam Symptom Checklist (RSCL) and the Hospital Anxiety and Depression Scale (HADS) at 10 time points. The principal aim of the analyses was to keep the methods simple, so as to allow the presentation and interpretation of the results to be as clear as possible. This was achieved by (1) considering individual symptoms rather than symptom subscales or domains, (2) assessing short-term effects (up to 3 months) and long-term effects (at 1 and 2 years) separately, and (3) for the short-term analyses, (a) splitting the data randomly into an exploratory data set and a confirmatory data set, and (b) using two different methods of analysis: a subject-specific approach, which used the area under the curve (AUC) as a summary measure, and a group-based method, which plotted the percent of patients with moderate or severe symptoms over time. RESULTS The results indicate that apart from CHART causing transient pain on swallowing and heartburn, there was little difference between the regimens in the short or long-term. CONCLUSION Combining the results of the patient-assessed symptom comparisons with the clinical results indicates that CHART confers a major benefit without serious morbidity.

Sign in / Sign up

Export Citation Format

Share Document